vs
拜玛林制药（BMRN）与Ryman Hospitality Properties, Inc.（RHP）财务数据对比。点击上方公司名可切换其他公司
拜玛林制药的季度营收约是Ryman Hospitality Properties, Inc.的1.3倍（$874.6M vs $664.6M），Ryman Hospitality Properties, Inc.净利率更高（10.4% vs -5.3%，领先15.8%），拜玛林制药同比增速更快（17.0% vs 13.2%），过去两年拜玛林制药的营收复合增速更高（16.1% vs 4.1%）
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
莱曼酒店地产是一家主营酒店、度假村、娱乐及媒体业务的企业，得名于旗下位于田纳西州纳什维尔的国家历史地标莱曼礼堂。公司历史可追溯至曾为俄克拉荷马出版公司子公司时期，1983年收购WSM公司后奠定现代业务基础，同时将知名演出IP大奥普里等核心资产纳入麾下。
BMRN vs RHP — 直观对比
营收规模更大
BMRN
是对方的1.3倍
$664.6M
营收增速更快
BMRN
高出3.9%
13.2%
净利率更高
RHP
高出15.8%
-5.3%
两年增速更快
BMRN
近两年复合增速
4.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $874.6M | $664.6M |
| 净利润 | $-46.6M | $69.4M |
| 毛利率 | 68.5% | — |
| 营业利润率 | -5.1% | 20.7% |
| 净利率 | -5.3% | 10.4% |
| 营收同比 | 17.0% | 13.2% |
| 净利润同比 | -137.3% | 10.1% |
| 每股收益（稀释后） | $-0.22 | $1.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRNRHP
| Q1 26 | — | $664.6M | ||
| Q4 25 | $874.6M | $737.8M | ||
| Q3 25 | $776.1M | $592.5M | ||
| Q2 25 | $825.4M | $659.5M | ||
| Q1 25 | $745.1M | $587.3M | ||
| Q4 24 | $747.3M | $647.6M | ||
| Q3 24 | $745.7M | $550.0M | ||
| Q2 24 | $712.0M | $613.3M |
净利润BMRNRHP
| Q1 26 | — | $69.4M | ||
| Q4 25 | $-46.6M | $74.5M | ||
| Q3 25 | $-30.7M | $34.9M | ||
| Q2 25 | $240.5M | $71.8M | ||
| Q1 25 | $185.7M | $63.0M | ||
| Q4 24 | $124.9M | $72.3M | ||
| Q3 24 | $106.1M | $59.0M | ||
| Q2 24 | $107.2M | $100.8M |
毛利率BMRNRHP
| Q1 26 | — | — | ||
| Q4 25 | 68.5% | 41.4% | ||
| Q3 25 | 82.0% | 40.9% | ||
| Q2 25 | 81.8% | 49.7% | ||
| Q1 25 | 79.7% | 44.4% | ||
| Q4 24 | 81.8% | 40.4% | ||
| Q3 24 | 74.7% | 43.1% | ||
| Q2 24 | 81.7% | 48.4% |
营业利润率BMRNRHP
| Q1 26 | — | 20.7% | ||
| Q4 25 | -5.1% | 19.4% | ||
| Q3 25 | -6.0% | 15.0% | ||
| Q2 25 | 33.5% | 21.1% | ||
| Q1 25 | 30.0% | 19.8% | ||
| Q4 24 | 21.6% | 18.6% | ||
| Q3 24 | 15.3% | 19.3% | ||
| Q2 24 | 16.9% | 27.4% |
净利率BMRNRHP
| Q1 26 | — | 10.4% | ||
| Q4 25 | -5.3% | 10.1% | ||
| Q3 25 | -4.0% | 5.9% | ||
| Q2 25 | 29.1% | 10.9% | ||
| Q1 25 | 24.9% | 10.7% | ||
| Q4 24 | 16.7% | 11.2% | ||
| Q3 24 | 14.2% | 10.7% | ||
| Q2 24 | 15.1% | 16.4% |
每股收益（稀释后）BMRNRHP
| Q1 26 | — | $1.03 | ||
| Q4 25 | $-0.22 | $1.12 | ||
| Q3 25 | $-0.16 | $0.53 | ||
| Q2 25 | $1.23 | $1.12 | ||
| Q1 25 | $0.95 | $1.00 | ||
| Q4 24 | $0.65 | $1.12 | ||
| Q3 24 | $0.55 | $0.94 | ||
| Q2 24 | $0.55 | $1.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $6.1B | $770.8M |
| 总资产 | $7.6B | $6.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BMRNRHP
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | $471.4M | ||
| Q3 25 | $1.3B | $483.3M | ||
| Q2 25 | $1.2B | $420.6M | ||
| Q1 25 | $1.0B | $413.9M | ||
| Q4 24 | $942.8M | $477.7M | ||
| Q3 24 | $675.4M | $534.9M | ||
| Q2 24 | $972.1M | $498.4M |
股东权益BMRNRHP
| Q1 26 | — | $770.8M | ||
| Q4 25 | $6.1B | $750.2M | ||
| Q3 25 | $6.1B | $758.5M | ||
| Q2 25 | $6.0B | $800.4M | ||
| Q1 25 | $5.8B | $531.5M | ||
| Q4 24 | $5.7B | $549.0M | ||
| Q3 24 | $5.4B | $551.9M | ||
| Q2 24 | $5.3B | $562.6M |
总资产BMRNRHP
| Q1 26 | — | $6.2B | ||
| Q4 25 | $7.6B | $6.2B | ||
| Q3 25 | $7.6B | $6.2B | ||
| Q2 25 | $7.5B | $6.1B | ||
| Q1 25 | $7.1B | $5.2B | ||
| Q4 24 | $7.0B | $5.2B | ||
| Q3 24 | $6.9B | $5.2B | ||
| Q2 24 | $7.1B | $5.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.6M | — |
| 自由现金流经营现金流 - 资本支出 | $58.9M | — |
| 自由现金流率自由现金流/营收 | 6.7% | — |
| 资本支出强度资本支出/营收 | 4.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $725.0M | — |
8季度趋势，按日历期对齐
经营现金流BMRNRHP
| Q1 26 | — | — | ||
| Q4 25 | $99.6M | $164.7M | ||
| Q3 25 | $368.7M | $205.2M | ||
| Q2 25 | $185.3M | $122.5M | ||
| Q1 25 | $174.4M | $98.2M | ||
| Q4 24 | $185.6M | $166.6M | ||
| Q3 24 | $221.5M | $218.1M | ||
| Q2 24 | $118.8M | $184.3M |
自由现金流BMRNRHP
| Q1 26 | — | — | ||
| Q4 25 | $58.9M | $58.5M | ||
| Q3 25 | $340.2M | $135.4M | ||
| Q2 25 | $168.2M | $53.0M | ||
| Q1 25 | $157.6M | $-14.5M | ||
| Q4 24 | $166.1M | $76.0M | ||
| Q3 24 | $203.0M | $85.7M | ||
| Q2 24 | $97.4M | $78.8M |
自由现金流率BMRNRHP
| Q1 26 | — | — | ||
| Q4 25 | 6.7% | 7.9% | ||
| Q3 25 | 43.8% | 22.9% | ||
| Q2 25 | 20.4% | 8.0% | ||
| Q1 25 | 21.2% | -2.5% | ||
| Q4 24 | 22.2% | 11.7% | ||
| Q3 24 | 27.2% | 15.6% | ||
| Q2 24 | 13.7% | 12.9% |
资本支出强度BMRNRHP
| Q1 26 | — | — | ||
| Q4 25 | 4.7% | 14.4% | ||
| Q3 25 | 3.7% | 11.8% | ||
| Q2 25 | 2.1% | 10.5% | ||
| Q1 25 | 2.3% | 19.2% | ||
| Q4 24 | 2.6% | 14.0% | ||
| Q3 24 | 2.5% | 24.1% | ||
| Q2 24 | 3.0% | 17.2% |
现金转化率BMRNRHP
| Q1 26 | — | — | ||
| Q4 25 | — | 2.21× | ||
| Q3 25 | — | 5.88× | ||
| Q2 25 | 0.77× | 1.71× | ||
| Q1 25 | 0.94× | 1.56× | ||
| Q4 24 | 1.49× | 2.30× | ||
| Q3 24 | 2.09× | 3.70× | ||
| Q2 24 | 1.11× | 1.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
RHP
| Food and beverage | $289.3M | 44% |
| Rooms | $223.8M | 34% |
| Entertainment | $79.2M | 12% |
| Other | $72.3M | 11% |
